Arena F, Peracchia G, Di Stefano C, Cortellini P
Divisione di Urologia, Azienda Ospedaliera di Parma.
Acta Biomed Ateneo Parmense. 1996;67(1-2):49-53.
A total of 118 patients entered into a pharmacological erection program using prostaglandin E1 (PGE1) from September 1994 to November 1995. Of the men 20 (16.9%) used PGE1 on a regular basis, median duration of drug use was 4 months with a range of 2 to 14 months, while 66 (55.9%) failed to continue in the program after the dose titration period, (median duration of drug use 6 weeks), 32 (27.1%) failed to initiate PGE1 pharmacological erection program. There have been no instances of cavernous fibrosis, systemic reaction, penile pain after injection or priapism (erection present longer than 4 hours) in any patient; 24 (20.3%) men were unable to achieve an adequate erection with PGE1 intracavernous injections. PGE1 appears to have a lower risk of prolonged erections than other intracavernous agents and will continue to increase in popularity. However we report an interesting number of men who fail to continue (55.9%) or fail to initiate (16.9%) PGE1 therapy.
1994年9月至1995年11月，共有118名患者参与了使用前列腺素E1（PGE1）的药物勃起治疗项目。其中，20名男性（16.9%）定期使用PGE1，药物使用的中位时长为4个月，范围在2至14个月；66名男性（55.9%）在剂量滴定期后未能继续参与该项目（药物使用中位时长为6周）；32名男性（27.1%）未能启动PGE1药物勃起治疗项目。所有患者均未出现海绵体纤维化、全身反应、注射后阴茎疼痛或阴茎异常勃起（勃起持续超过4小时）的情况；24名男性（20.3%）通过海绵体内注射PGE1无法获得足够的勃起。与其他海绵体内药物相比，PGE1出现长时间勃起的风险似乎更低，其受欢迎程度也将持续上升。然而，我们报告了相当数量未能继续（55.9%）或未能启动（16.9%）PGE1治疗的男性患者。
